273 related articles for article (PubMed ID: 2475847)
21. [Effects of transurethral resection on the serum concentration of prostate specific antigen and prostatic acid phosphatase].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(5):356-7. PubMed ID: 1705076
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer-associated markers.
Chu TM
Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
[TBL] [Abstract][Full Text] [Related]
23. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
Svanholm H; Hørder M
Scand J Urol Nephrol Suppl; 1988; 107():65-70. PubMed ID: 2453920
[TBL] [Abstract][Full Text] [Related]
24. Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology.
Panteghini M; Pagani F; Bonora R
Eur J Clin Chem Clin Biochem; 1992 Mar; 30(3):135-9. PubMed ID: 1376155
[TBL] [Abstract][Full Text] [Related]
25. The value of prostate-specific antigen in the management of localized prostatic cancer.
Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
[TBL] [Abstract][Full Text] [Related]
26. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
Wymenga LF; Mensink HJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
[TBL] [Abstract][Full Text] [Related]
27. [Experience with prostate-specific antigen in patients with prostatic cancer].
Romics I; Bach D
Orv Hetil; 1989 Dec; 130(52):2797-800. PubMed ID: 2481833
[TBL] [Abstract][Full Text] [Related]
28. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
29. [The role of PSA in prostatic adenocarcinoma].
Manca GP
Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
[TBL] [Abstract][Full Text] [Related]
30. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
31. The present role of prostatic specific antigen (PSA) as a tumor marker in carcinoma of the prostate.
Parra RO
Mo Med; 1991 Jun; 88(6):349-52. PubMed ID: 1712422
[TBL] [Abstract][Full Text] [Related]
32. [Prostatic specific antigen and prostatic pathology. Value of preoperative blood assay. Preliminary study apropos of 709 case reports].
Bordes M; Brunet-Lecomte P; Dusserre P; Dusserre-Guion L; Michiels-Marzais D; Morlevat F; Peny J; Roignot P; Colas JM; Ferry N
Ann Urol (Paris); 1989; 23(4):295-300. PubMed ID: 2480077
[TBL] [Abstract][Full Text] [Related]
33. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
[No Abstract] [Full Text] [Related]
34. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
35. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
36. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
Yoshiki T; Okada K; Oishi K; Yoshida O
Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
[TBL] [Abstract][Full Text] [Related]
37. [Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen].
Mathieu MC; Caillaud JM
Bull Cancer; 1985; 72(5):405-13. PubMed ID: 2416371
[TBL] [Abstract][Full Text] [Related]
38. [Prostate-specific antigen in prostatic pathology].
Teillac P; Peyret C; Leroy M; Najean Y; Le Duc A
Ann Urol (Paris); 1988; 22(3):193-6. PubMed ID: 2456712
[TBL] [Abstract][Full Text] [Related]
39. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
40. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer.
Wang TY; Kawaguchi TP
Ann Clin Lab Sci; 1986; 16(6):461-6. PubMed ID: 3800301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
